US Patent

US11717555 — Pharmaceutical compositions having a selected release duration

Formulation · Assigned to Foresee Pharmaceuticals Co Ltd · Expires 2039-01-01 · 13y remaining

Vulnerability score 50/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects a stabilized biodegradable polymeric composition for controlled release delivery of peptide agents, such as leuprolide mesylate.

USPTO Abstract

The present invention provides for a stabilized biodegradable polymeric composition useful as a controlled release delivery system for peptide agents. The compositions of the present invention comprise a) a strong acid salt of a LHRH agonist or antagonist; b) a biodegradable polymer of poly(lactide-co-glycolide), wherein the ratio of lactide:glycolide of the copolymer is from 50:50 to about 100:0; and c) N-methyl-2-pyrrolidone (NMP), wherein the composition does not contain excess strong acid in addition to the strong acid used to form the salt of the LHRH agonist or antagonist. The composition, when injected, can provide a controlled release of leuprolide for a period of up to 6 months.

Drugs covered by this patent

Patent Metadata

Patent number
US11717555
Jurisdiction
US
Classification
Formulation
Expires
2039-01-01
Drug substance claim
No
Drug product claim
Yes
Assignee
Foresee Pharmaceuticals Co Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.